AIM ImmunoTech Files S-1 for Public Offering

TL;DR

AIM ImmunoTech filing S-1 for a public offering. Potential capital raise incoming.

AI Summary

AIM ImmunoTech Inc. filed an S-1 form on January 23, 2025, indicating a public offering of its securities. The company, previously known as Hemispherx Biopharma Inc., is focused on biological products and is incorporated in Delaware. Their business address is located at 2117 SW Highway 484, Ocala, FL 32801.

Why It Matters

This S-1 filing signals AIM ImmunoTech's intention to raise capital through a public offering, which could fund further research and development or expansion of its product pipeline.

Risk Assessment

Risk Level: medium — S-1 filings often indicate a company is seeking to raise capital, which can be a positive sign but also carries inherent risks associated with public offerings and the company's specific financial situation.

Key Numbers

• 333-284443 — SEC File Number (Identifies this specific SEC filing)
• 25551045 — Film Number (Internal SEC processing number)

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Filer of the S-1 form
• Hemispherx Biopharma Inc. (company) — Former name of AIM ImmunoTech Inc.
• 2117 SW Highway 484, Ocala, FL 32801 (location) — Business and mailing address
• January 23, 2025 (date) — Filing date of the S-1 form

FAQ

Key Financial Figures

• $0.001 — of one share of common stock, par value $0.001 per share, one Class A warrant ("Class
• $0 — k at an assume public offering price of $0.~ per Unit for gross proceeds of approx
• $6,000,000 — ty is less than the required minimum of $6,000,000. Pursuant to the letter from the Exchan
• $2.9 million — 30, 2024, our stockholders' equity was $2.9 million. We must increase our stockholders' equ
• $6 million — our stockholders' equity to be at least $6 million to regain compliance with this rule. If

Filing Documents

• forms-1.htm (S-1) — 4051KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 65KB
• forms-1_001.jpg (GRAPHIC) — 19KB
• 0001493152-25-003444.txt ( ) — 15355KB
• aim-20240930.xsd (EX-101.SCH) — 81KB
• aim-20240930_cal.xml (EX-101.CAL) — 87KB
• aim-20240930_def.xml (EX-101.DEF) — 396KB
• aim-20240930_lab.xml (EX-101.LAB) — 607KB
• aim-20240930_pre.xml (EX-101.PRE) — 493KB
• forms-1_htm.xml (XML) — 3064KB

RISK FACTORS

RISK FACTORS 7 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND SUMMARY RISK FACTORS 20

USE OF PROCEEDS

USE OF PROCEEDS 22 CAPITALIZATION 23

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 25

BUSINESS

BUSINESS 34 MANAGEMENT 53 EXECUTIVE AND DIRECTOR COMPENSATION 56 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 63 PRINCIPAL STOCKHOLDERS 63

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 64 PLAN OF DISTRIBUTION 68 LEGAL MATTERS 74 EXPERTS 74 WHERE YOU CAN FIND MORE INFORMATION 74 i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus and in any free writing prospectus. We have not and the placement agent has not authorized anyone to provide you with information different from that contained in this prospectus. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Neither we nor the placement agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside of the United States. 1 PROSPECTUS SUMMARY This summary contains basic information about us and this offering. Because it is a summary, it does not contain all of the information that you should consider before investing. Before you decide to invest in our securities, you should read this entire prospectus carefully, including the section entitled "Risk Factors." Unless the context otherwise requires, references in this prospectus to "AIM," "the Company," "we," "us" and "our" refer to AIM ImmunoTech Inc. and our subsidiaries. Our

Business

Business AIM ImmunoTech Inc. and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders and to treat cancers for which there are currently inadequate or unmet therapies. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. Our flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA ("dsRNA") molecule being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has not been approved by the Food and Drug Administration (the "FDA") or marketed in the United States, but is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome ("CFS"). We are currently proceeding primarily in four areas: Conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer. Evaluating Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors. Exploring Ampligen's antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. Evaluating Ampligen as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and fatigue and/or the Post-COVID condition of fatigue. We are prioritizing activities in an order related to the stage of development, with those clinical activities such as pancreatic cancer, ME/CFS and Post-COVID conditio

View Full Filing

View this S-1 filing on SEC EDGAR